Rein Therapeutics, Inc. Common Stock RNTX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Cost of Goods Sold by Product | ||||||
| License And Maintenance | $9K0.0% | $8K0.0% | $18K0.0% | $0— | $9K0.0% | |
| License | $0— | $0— | $25K— | $0— | $0-100% | |
| Research And Development Expense by Product | ||||||
| Clinical Operation Activities | $1.96M+191% | $1.04M+7.4% | $414K-66.2% | $2.16M+212% | $673K-34.7% | |
| CMC Activities | $520K-7.1% | $571K+232% | $272K-71.3% | $836K-55.8% | $560K-60.6% | |
| Employee Related Expenses | $500K-19.6% | $497K-18.1% | $478K-7.5% | $521K+11.1% | $622K+2.6% | |
| Facilities And Other Expenses | $25K+56.3% | $13K0.0% | $24K+20.0% | $21K+75.0% | $16K+700% | |
| Preclinical Study Costs | $0-100% | —— | $294K-65.9% | $267K-48.2% | $556K+578% | |
| Professional Fees For Services | $0-100% | $0— | $6K-80.6% | $21K-44.7% | $17K+185% | |
| General And Administrative Expense by Product | ||||||
| Employee Related Expenses | $859K-9.3% | $939K+57.8% | $927K-18.2% | $935K-63.2% | $947K-21.1% | |
| Facilities And Other Expenses | $508K+8.1% | $421K-6.4% | $464K+19.9% | $608K-20.2% | $470K-13.3% | |
| Professional Fees For Services | $790K-30.6% | $598K-58.2% | $2.42M+192% | $1.04M-48.1% | $1.14M-43.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rein Therapeutics, Inc. Common Stock break its business down?
- Rein Therapeutics, Inc. Common Stock (RNTX) reports cost of goods sold by product across 2 parts — License And Maintenance and License. Each is extracted from the segment footnotes and tracked over time.
- Where does Rein Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rein Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.